[go: up one dir, main page]

BR0312696A - Tratamento tópico de doenças da pele - Google Patents

Tratamento tópico de doenças da pele

Info

Publication number
BR0312696A
BR0312696A BR0312696-0A BR0312696A BR0312696A BR 0312696 A BR0312696 A BR 0312696A BR 0312696 A BR0312696 A BR 0312696A BR 0312696 A BR0312696 A BR 0312696A
Authority
BR
Brazil
Prior art keywords
skin diseases
topical treatment
topical
treatment
inflammatory
Prior art date
Application number
BR0312696-0A
Other languages
English (en)
Inventor
Chris Rundfeldt
Manfred Kietzmann
Joachim Hoppmann
Wolfgang Boumer
Hildegard Kuss
Norbert Hoefgen
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of BR0312696A publication Critical patent/BR0312696A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"TRATAMENTO TóPICO DE DOENçAS DA PELE". A presente invenção refere-se a um método para o tratamento de uma doença inflamatória e/ou alérgica da pele compreendendo administração tópica de um hidróxi indol substituído.
BR0312696-0A 2002-07-11 2003-07-10 Tratamento tópico de doenças da pele BR0312696A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39522102P 2002-07-11 2002-07-11
PCT/EP2003/007514 WO2004006920A1 (en) 2002-07-11 2003-07-10 Topical treatment of skin diseases

Publications (1)

Publication Number Publication Date
BR0312696A true BR0312696A (pt) 2005-04-26

Family

ID=30115840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312696-0A BR0312696A (pt) 2002-07-11 2003-07-10 Tratamento tópico de doenças da pele

Country Status (20)

Country Link
US (1) US20040038958A1 (pt)
EP (1) EP1531818A1 (pt)
JP (1) JP2005537262A (pt)
KR (1) KR20050021464A (pt)
CN (1) CN1681500A (pt)
AR (1) AR040647A1 (pt)
AU (1) AU2003254332B2 (pt)
BR (1) BR0312696A (pt)
CA (1) CA2492093A1 (pt)
HR (1) HRP20050133A2 (pt)
IL (1) IL166016A0 (pt)
MX (1) MXPA05000486A (pt)
NO (1) NO20050718L (pt)
NZ (1) NZ537482A (pt)
PL (1) PL375487A1 (pt)
RU (1) RU2005103608A (pt)
TW (1) TW200410690A (pt)
UA (1) UA80711C2 (pt)
WO (1) WO2004006920A1 (pt)
ZA (1) ZA200500108B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
BR0313825A (pt) 2002-08-29 2005-07-12 Merck & Co Inc Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
WO2004107678A2 (en) * 2003-05-28 2004-12-09 Artimi Ltd Ultra-wideband network, device, device controller, method and data packet for establishing a mesh network and forwarding packets on another channel
EP1713473B1 (en) * 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
JP4700014B2 (ja) * 2004-02-06 2011-06-15 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 呼吸器系疾患の治療用の抗コリン作用薬及び４型ホスホジエステラーゼの組合せ剤
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
JP4961131B2 (ja) * 2004-10-29 2012-06-27 田辺三菱製薬株式会社 皮膚損傷治療剤
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
CN101370775A (zh) * 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
PL1992622T3 (pl) 2006-02-21 2012-01-31 Eisai R&D Man Co Ltd Pochodna 4-(3-benzoiloaminofenylo)-6,7-dimetoksy-2-metyloaminochinazoliny
CA2678477A1 (en) 2007-02-16 2008-08-21 Eisai R&D Management Co., Ltd. Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid
TWI414296B (zh) 2007-08-17 2013-11-11 Eisai R&D Man Co Ltd Innovative agents
WO2009025238A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. キナゾリン誘導体の製造方法
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
EP3201203B1 (en) 2014-09-29 2021-05-19 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
AU6821294A (en) * 1993-04-30 1994-11-21 Rodner R. Winget Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
UA59443C2 (uk) * 1998-04-28 2003-09-15 Арцнайміттельверк Дрезден Гмбх Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання

Also Published As

Publication number Publication date
NZ537482A (en) 2006-09-29
NO20050718L (no) 2005-04-01
EP1531818A1 (en) 2005-05-25
MXPA05000486A (es) 2005-07-22
AU2003254332A1 (en) 2004-02-02
WO2004006920A1 (en) 2004-01-22
UA80711C2 (en) 2007-10-25
US20040038958A1 (en) 2004-02-26
AR040647A1 (es) 2005-04-13
AU2003254332B2 (en) 2009-01-08
JP2005537262A (ja) 2005-12-08
CA2492093A1 (en) 2004-01-22
ZA200500108B (en) 2005-02-23
KR20050021464A (ko) 2005-03-07
PL375487A1 (en) 2005-11-28
CN1681500A (zh) 2005-10-12
RU2005103608A (ru) 2005-06-27
TW200410690A (en) 2004-07-01
IL166016A0 (en) 2006-01-15
HRP20050133A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
BR0312696A (pt) Tratamento tópico de doenças da pele
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
PT1100516E (pt) Extratos de matricaria (tanacetum parthenium) contra doencas inflamatorias
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BR0312232A (pt) Inibidores de caspases e seus usos
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
BRPI0413083A (pt) métodos para tratar inflamação e doenças associadas com inflamação com uma estatina e éter
BRPI0512841A (pt) composições e métodos para o tratamento de infecções patológicas
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012.